Hercules, CA — November 27, 2013 — Bio-Rad Laboratories, Inc. today announced the launch of its CFX Manager software version 3.1. The software allows users to quickly and easily set up a real-time PCR experiment, assess data quality, and interpret results.
Bio-Rad’s CFX Manager software is compatible with all CFX platforms and features optimized run files for Bio-Rad’s wet-lab validated PrimePCR™ primer and probe assays, saving researchers time and money.
The updated CFX Manager software includes new features for allelic discrimination, including automatic genotype call assignments based on a proprietary clustering algorithm, the option to change calls directly in the allelic discrimination chart, and a feature that allows users to view a map of the calls directly on the plate view.
Version 3.1 also includes an improved CFX qualification plate workflow that enables researchers to verify the performance of the CFX real-time PCR system with just a few clicks. A PDF report with pass/fail results for each criterion is automatically generated after the experiment to help users assess their instrument’s performance.
For users that require mandatory login and audit trails for 21 CFR Part 11 compliance, the security edition of the software is now compatible with all of Bio-Rad’s CFX real-time PCR detection systems, including the CFX96 Touch™ and CFX384 Touch™ systems.
For more information on Bio-Rad’s CFX Manager software, please visit www.bio-rad.com/CFX-Manager3.1.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,600 people worldwide and had revenues exceeding $2 billion in 2012. Visit us at www.bio‑rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc. is licensed by Life Technologies Corporation to sell reagents containing SYBR® Green I for use in real-time PCR, for research purposes only.
For more information contact:
312-997-2436 x 112